References
- Recent Advances in SPECT Imaging Mark T. Madsen Journal of Nuclear Medicine Apr 2007, 48 (4) 661–673; DOI: 10.2967/jnumed.106.032680.
- Schillaci, O. Hybrid SPECT/CT: a new era for SPECT imaging?. Eur J Nucl Med Mol Imaging 32, 521–524 (2005). https://doi.org/10.1007/s00259–005–1760–9.
- Bailey DL, Townsend DW, Valk PE, Maisy MN (2005). Positron Emission Tomography: Basic Sciences. Secaucus, NJ: Springer-Verlag. ISBN 978–1-85233–798–8)
- Medycyna nuklearna – wprowadzenie do diagnostyki i terapii radioizotopowej [Cyprian Świętaszczyk], 2014.
- Mark Muzi, Scott D Freeman, Robert C Burrows, Robert W Wiseman, Jeanne M Link, Kenneth A Krohn, Michael M Graham, Alexander M Spence, Kinetic characterization of hexokinase isoenzymes from glioma cells: Implications for FDG imaging of human brain tumors, Nuclear Medicine and Biology, Volume 28, Issue 2, 2001, https://doi.org/10.1016/S0969–8051(00)00201–8.
- Miles KA, Williams RE. Warburg revisited: imaging tumour blood flow and metabolism. Cancer Imaging. 2008 Mar 25;8(1):81–6. doi: 10.1102/1470–7330.2008.0011. PMID: 18390391; PMCID: PMC2324371.
- Finessi, M., Bisi, G. & Deandreis, D. Hyperglycemia and 18F-FDG PET/CT, issues and problem solving: a literature review. Acta Diabetol 57, 253–262 (2020). https://doi.org/10.1007/s00592–019–01385–8.
- Berrouschot, J., Barthel, H., Hesse, S., Köster, J., Knapp, W. H., & Schneider, D. (1998). Differentiation between Transient Ischemic Attack and Ischemic Stroke within the First Six Hours after Onset of Symptoms by Using99m Tc-ECD-SPECT. Journal of Cerebral Blood Flow & Metabolism, 18(8), 921–929. https://doi.org/10.1097/00004647–199808000–00013.
- van Paesschen, W. (2004). Ictal SPECT. Epilepsia, 45(s4), 35–40. https://doi.org/10.1111/j.0013–9580.2004.04008.x.
- Valotassiou, V., Malamitsi, J., Papatriantafyllou, J., Dardiotis, E., Tsougos, I., Psimadas, D., Alexiou, S., Hadjigeorgiou, G., & Georgoulias, P. (2018). SPECT and PET imaging in Alzheimer’s disease. Annals of Nuclear Medicine, 32(9), 583–593. https://doi.org/10.1007/s12149–018–1292–6.
- Abdel-Dayem HM, Sadek SA, Kouris K, et al: Changes in cerebral perfusion after acute head injury: Comparison of CT with Tc-99m HM-PA0 SPECT. Radiology 165:221–226,1987.
- Fond, G., Garosi, A., Faugere, M., Campion, J.-Y., Lancon, C., Boyer, L., Richieri, R., & Guedj, E. (2022). Peripheral inflammation is associated with brain SPECT perfusion changes in schizophrenia. European Journal of Nuclear Medicine and Molecular Imaging, 49(3), 905–912. https://doi.org/10.1007/s00259–021–05529–3.
- Andersen A. R. (1989). 99mTc-D,L-hexamethylene-propyleneamine oxime (99mTc-HMPAO): basic kinetic studies of a tracer of cerebral blood flow. Cerebrovascular and Brain Metabolism Reviews, 1(4), 288–318. https://pubmed.ncbi.nlm.nih.gov/2701656/
- van Dyck, C. H., Lin, C. H., Smith, E. O., Wisniewski, G., Cellar, J., Robinson, R., Narayan, M., Bennett, A., Delaney, R. C., Bronen, R. A., & Hoffer, P. B. (1996). Comparison of technetium-99m--HMPAO and technetium-99m-ECD cerebral SPECT images in Alzheimer’s disease. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 37(11), 1749–1755.
- Vallabhajosula, S., Zimmerman, R. E., Picard, M., Stritzke, P., Mena, I., Hellman, R. S., Tikofsky, R. S., Stabin, M. G., Morgan, R. A., & Goldsmith, S. J. (1989). Technetium-99m ECD: a new brain imaging agent: in vivo kinetics and biodistribution studies in normal human subjects. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 30(5), 599–604.
- Baird, A. E., Austin, M. C., McKay, W. J., & Donnan, G. A. (1997). Sensitivity and Specificity of 99m Tc-HMPAO SPECT Cerebral Perfusion Measurements During the First 48 Hours for the Localization of Cerebral Infarction. Stroke, 28(5), 976–980. https://doi.org/10.1161/01.STR.28.5.976.
- Infeld, B., Davis, S. M., Donnan, G. A., Lichtenstein, M., Baird, A. E., Binns, D., Mitchell, P. J., & Hopper, J. L. (1996). Streptokinase Increases Luxury Perfusion After Stroke. Stroke, 27(9), 1524–1529. https://doi.org/10.1161/01.STR.27.9.1524.
- Oku, N., Kashiwagi, T., & Hatazawa, J. (2010). Nuclear neuroimaging in acute and subacute ischemic stroke. Annals of Nuclear Medicine, 24(9), 629–638. https://doi.org/10.1007/s12149–010–0421–7.
- Devous MD, Thisted R, Rowe CC, et al: SPECT brain imaging in epilepsy: A meta analysis. J Nucl Med 35 (5 suppl): 31, 1994.
- Sarikaya I. PET studies in epilepsy. Am J Nucl Med Mol Imaging. 2015 Oct 12;5(5):416–30. PMID: 26550535; PMCID: PMC4620171.
- Sperk, G., Furtinger, S., Schwarzer, C., Pirker, S. (2004). GABA and Its Receptors in Epilepsy. In: Binder, D.K., Scharfman, H.E. (eds) Recent Advances in Epilepsy Research. Advances in Experimental Medicine and Biology, vol 548. Springer, Boston, MA. https://doi.org/10.1007/978–1-4757–6376–8_7.
- Yankam Njiwa, J., Gray, K.R., Costes, N., Mauguiere, F., Ryvlin, P., Hammers, A., 2015. Advanced [(18)F]FDG and [(11)C]flumazenil PET analysis for individual outcome prediction after temporal lobe epilepsy surgery for hippocampal sclerosis. Neuroimage Clin. 7, 122–131. https://doi.org/10.1016/j.nicl.2014.11.013.
- Sloviter RS. Permanently altered hippocampal structure, excitability, and inhibition after experimental status epilepticus in the rat: the „dormant basket cell” hypothesis and its possible relevance to temporal lobe epilepsy. Hippocampus. 1991 Jan;1(1):41–66. doi:10.1002/hipo.450010106. PMID: 1688284.
- Vallone D., Picetti R., Borrelli E.: Structure and function of dopamine receptors. Neurosci. Biobehav. Rev., 2000; 24: 125–132.
- Włodzimierz Januszewicz, Mariola Pęczkowska, Katarzyna Michel-Rowicka, Aleksander Prejbisz, Andrzej Januszewicz: Dopamina — aspekty patofizjologiczne i kliniczne.
- Jakub Drożak, Jadwiga Bryła: Dopamina – nie tylko neuroprzekaźnik, Postepy Hig Med Dosw. (online), 2005; 59: 405–420.
- Klein M., Battagello D., Cardoso A., et al.:Dopamine: Functions, Signaling, and Association with Neurological Diseases, Cellular and Molecular Neurobiology, (2019), 31–59, 39(1)
- Armstrong, Melissa J. Okun, Michael S.: Diagnosis and Treatment of Parkinson Disease: A Review JAMA – Journal of the American Medical Association, (2020), 548–560, 323(6)
- Gaweł M., Potulska-Chromik A., Choroby neurodegeneracyjne: choroba Alzheimera i Parkinsona, Postępy Nauk Medycznych, t. XXVIII, nr 7, 2015, s. 473;
- Krygowska-Wajs A. Przedkliniczny i wczesny okres choroby Parkinson diagnostyka i możliwości leczenia neuroprotekcyjnego, Polski Przegląd Neurologiczny, (2006), 177–182, 2.
- Akdemır Ü., Bora Tokçaer A., Atay L.: Dopamine transporter SPECT imaging in Parkinson’s disease and parkinsonian disorders Turkish Journal of Medical Sciences, (2021), 400–410, 51(2)
- Bajaj, N., Hauser, R. A., & Grachev, I. D. (2013). Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes. Journal of Neurology, Neurosurgery & Psychiatry, 84(11), 1288–1295.
- David J. Brooks: Imaging Approaches to Parkinson Disease, Journal of Nuclear Medicine, (2010), 596–609, 51(4)
- Piotr Alster, Dariusz Koziorowski, Leszek Królicki, Andrzej Friedman: Radioznaczniki wykorzysty-wane w pozytonowej tomografii emisyjnej w badaniach otępienia z ciałami Lewy’ego. Pol. Przegl. Neurol 2017;13(4):186–188.
- Paulina Cegła, Beata Chrapko, Katarzyna Pietrasz, Witold Cholewiński: Zastosowanie PET/CT w neurologii, Inżynier i Fizyk Medyczny, 8(2).
- Calabria FF, Calabria E, Gangemi V, Cascini GL. Current status and future challenges of brain imaging with (18)F-DOPA PET for movement disorders. Hell J Nucl Med. 2016 Jan-Apr;19(1):33–41.
- Wagner, J.D., Schauwecker, D.S., Davidson, D., Wenck, S., Jung, S.-H. and Hutchins, G. (2001), FDG–PET sensitivity for melanoma lymph node metastases is dependent on tumor volume. J. Surg. Oncol., 77: 237–242. https://doi.org/10.1002/jso.1102.
- Detection of Distant Metastases in Esophageal Cancer with 18F-FDG PET, Pierre A.M. Heeren, Pieter L. Jager, Fons Bongaerts, Hendrik van Dullemen, Wim Sluiter, John Th.M. Plukker, Journal of Nuclear Medicine Jun 2004, 45 (6) 980–987;
- Verboom, P., van Tinteren, H., Hoekstra, O.S. et al. Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study. Eur J Nucl Med Mol Imaging 30, 1444–1449 (2003). https://doi.org/10.1007/s00259–003–1199–9.
- Strickland, Marie, and Elizabeth A. Stoll. „Metabolic reprogramming in glioma.” Frontiers in cell and developmental biology 5 (2017): 43.
- Quartuccio, Natale, et al. „The additional value of 18F-FDG PET and MRI in patients with glioma: a review of the literature from 2015 to 2020.” Diagnostics 10.6 (2020): 357.
- Plotkin, Michail, et al. „Comparison of F-18 FET-PET with F-18 FDG-PET for biopsy planning of non-contrast-enhancing gliomas.” European radiology 20 (2010): 2496–2502.
- Pirotte, Benoit, et al. „Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas.” Journal of Nuclear Medicine 45.8 (2004): 1293–1298.
- Dankbaar, J. W., et al. „The use of 18 F-FDG PET to differentiate progressive disease from treatment induced necrosis in high grade glioma.” Journal of neuro-oncology 125 (2015): 167–175.
- Nawashiro, Hiroshi, et al. „High expression of L-type amino acid transporter 1 in infiltrating glioma cells.” Brain tumor pathology 22 (2005): 89–91.
- Dunet, Vincent, et al. „Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis.” Neuro-oncology 18.3 (2015): 426–434.
- Zhang, Hong, et al. „Molecular imaging-guided theranostics and personalized medicine.” BioMed Research International 2012 (2012).
- Hjorthaug, Karin, et al. „Accuracy of 18F-FDG PET-CT in triaging lung cancer patients with suspected brain metastases for MRI.” Nuclear medicine communications 36.11 (2015): 1084–1090.
- Królicki, Leszek, et al. „225Ac-and 213Bi-substance P analogues for glioma therapy.” Seminars in Nuclear Medicine. Vol. 50. No. 2. WB Saunders, 2020.
- Królicki, Leszek, et al. „Locoregional Treatment of Glioblastoma With Targeted α Therapy:[: 213: Bi] Bi-DOTA–Substance P Versus [: 225: Ac] Ac-DOTA–Substance P—Analysis of Influence Parameters.” Clinical Nuclear Medicine (2022): 10–1097.